NCT00002663
- Conditions
- Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +44 more
- Locations
-
- Memorial Sloan Kettering Cancer Center New York, United States
Clinical trial condition
Lymphoma, B-Cell, Marginal Zone
Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.
646 public trials
88 recruiting studies
Lymphoma, B-Cell, Marginal Zone trial results
NCT02257242
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +28 more
- Locations
-
- Rhode Island Hospital and The Miriam Hospital Providence, Rhode Island, United States
NCT02853370
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Créteil (Hôpital Henri Mondor) Créteil, France
- Dijon (CHU de Dijon - Hôpital d'Enfants) Dijon, France
- Grenoble cedex 9 (CHU Michallon) Grenoble, France
- Le Kremlin Bicêtre (Hôpital Bicêtre) Le Kremlin-Bicêtre, France
Completed
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
NCT03276468
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +14 more
- Locations
-
- CHU d'Angers Angers, France
- CHU de Caen Caen, France
- CHU de Clermont Ferrand - Estaing Clermont-Ferrand, France
- Hopital Henri Mondor Créteil, France
NCT01947140
- Conditions
- Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +44 more
- Locations
-
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
- Columbia University Irving Medical Center New York, United States
- Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
NCT01647971
- Conditions
- B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +33 more
- Locations
-
- TG Therapeutics Investigational Trial Site Huntsville, Alabama, United States
- TG Therapeutics Investigational Trial Site Jonesboro, Arkansas, United States
- TG Therapeutics Investigational Trial Site Athens, Georgia, United States
- TG Therapeutics Investigational Trial Site Macon, Georgia, United States
NCT03019666
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Diffuse Large B Cell Lymphoma, +27 more
- Locations
-
- Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States
NCT00053157
- Conditions
- Bone Marrow Diseases, Burkitt Lymphoma, Chronic Disease, +55 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
Completed
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
NCT02049541
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, +28 more
- Locations
-
- Emory University Atlanta, Georgia, United States
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States
NCT01261247
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +66 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic Rochester, Minnesota, United States